Brown Advisory Inc Ultragenyx Pharmaceutical Inc. Transaction History

Brown Advisory Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$38.89 - $77.3 $8.82 Million - $17.5 Million	-226,734 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$71.81 - $90.15 $12.7 Million - $16 Million	-177,079 Reduced 43.85%	226,734 $17.3 Million
Q2 2018 Aug 10, 2018	BUY	$48.54 - $85.31 $33,152 - $58,266	683 Added 0.17%	403,813 $31 Million
Q1 2018 Jun 28, 2018	BUY	$44.33 - $58.52 $7.5 Million - $9.9 Million	169,141 Added 72.29%	403,130 $20.6 Million
Q1 2018 May 14, 2018	SELL	$44.33 - $58.52 $5.29 Million - $6.98 Million	-119,313 Reduced 33.77%	233,989 $11.9 Million
Q4 2017 Feb 12, 2018	BUY	$43.54 - $57.32 $505,064 - $664,912	11,600 Added 3.39%	353,302 $16.4 Million
Q3 2017 Nov 13, 2017	BUY	$49.79 - $66.32 $956,216 - $1.27 Million	19,205 Added 5.96%	341,702 $18.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	322,497	322,497 $20 Million

325

85.6M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.06B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.